LumiraDx Presents its POC Diagnostics Platform and Broad Test Menu at MEDICA 2022

By HospiMedica International staff writers
Posted on 13 Oct 2022

Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)

LumiraDx (London, UK) is presenting its innovative, next generation POC diagnostics platform and broad test menu together with its Fast Lab Solutions at the 2022 edition of MEDICA, the world’s largest medical trade fair.

At MEDICA 2022, LumiraDx is presenting the LumiraDx Point of Care Diagnostic Platform, an innovative, next generation POC system that combines a small, portable instrument, advanced low cost test strip and seamless digital connectivity. Its proprietary technology enables it to deliver exceptional point of care clinical performance, while being simple and easy to use. The company is also showcasing the LumiraDx INR Test, an enzyme kinetic assay based on Thrombin activity. The coagulation cascade is activated by the test reagents and INR is calculated from the measured PT-time. Haematocrit is also measured on the strip to ensure patients are within the 25-55% range. The accuracy of the LumiraDx INR Test is comparable to the ACL Elite lab reference method. In addition, LumiraDx is highlighting the LumiraDx D-Dimer Test, a rapid microfluidic immunoassay for the quantitative determination of D-Dimer and the only D-Dimer Test to provide fast, accurate, quantitative results in just six minutes from a fingerstick blood sample.

Among its COVID-19 tests being highlighted at MEDICA 2022 is the LumiraDx SARS-CoV-2 Ag Test, a rapid microfluidic immunoassay for detecting SARS-CoV-2 antigen. The test uses nasal and nasopharyngeal swab samples to detect antigen nucleocapsid protein in under 12 minutes at POC. In clinical studies, the LumiraDx SARS-CoV-2 antigen test demonstrated 97.6% positive agreement versus RT-PCR in patients tested within 12 days of the onset of symptoms. The company is also showcasing LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform, the test delivers rapid results at the POC.

Related Links:
LumiraDx